Company: BLLN
Filing Date: 2025-09-17
Form Type: DRS/A
Source: 0001193125-25-206347
Chunk: 97

Company: BillionToOne, Inc.
Filing Date: 2025-09-17
Form: DRS/A
Chunk 97
---
 in return for referring a patient or patronage to a laboratory; or paying or offering any remuneration (including any    
 kickback, bribe or rebate) directly or indirectly, overtly or covertly, in cash or in kind, to induce a referral of an individual to a laboratory or in exchange for an individual using the services of that laboratory billed to either commercial 
 third-party payors or government payors;                                                                                                                                                                                                             |

| • |     | the Stark Law and similar state laws, which prohibits a physician from making a referral for certain designated health                                                                                                                                   
 services covered by the Medicare or Medicaid program, including laboratory and pathology services, if the physician or an immediate family member of the physician has a financial relationship with the entity providing the designated health services 
 and prohibits that entity from billing, presenting or causing to be presented a claim for the designated health services furnished pursuant to the prohibited referral, unless an exception applies;                                                     |

| • |     | the federal Civil Monetary Penalties Law, which prohibits, among other things, the offering or transfer of remuneration to                                                                                                                     
 a Medicare or state healthcare program beneficiary if the person knows or should know it is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier of services reimbursable by Medicare or a state 
 healthcare program, unless an exception applies;                                                                                                                                                                                               |

| • |     | federal and state “Anti-Markup” rules, which, among other things, typically prohibit a physician or supplier                                                                                                                       
 billing for molecular diagnostic tests (with certain exceptions) from marking up the price of a purchased test performed by another physician or supplier that does not “share a practice” with the billing physician or supplier; |

| • |     | the federal government may bring a lawsuit under the False Claims Act (FCA), against any party whom it believes has                                                                                                                                       
 knowingly or recklessly presented, or caused to be presented, a false or fraudulent request for payment from the federal government, or who has made a false statement or used a false record to get a claim for payment approved. The federal government 
 and a number of courts have taken the position that claims presented in violation of certain other statutes, including the AKS or the Stark Law, can also be considered a violation of the FCA based on the theory that a provider impliedly certifies    
 compliance with all applicable laws, regulations, and other rules when submitting claims for reimbursement;                                                                                                                                               |

| • |     | the HIPAA fraud and abuse provisions, which created federal criminal